Tote 2.0 Introduction

The Gen 2 Tote by Phononic is spearheading a revolution in the solid-state cold storage industry. This groundbreaking product is redefining the way temperature-sensitive goods are stored, transported, and delivered, offering unprecedented levels of efficiency, reliability, and sustainability.

With its state-of-the-art solid-state cooling technology, the Gen 2 Tote is replacing traditional refrigeration methods with a compact, energy-efficient, and precise solution. By eliminating the need for bulky compressors and relying on advanced thermoelectric modules, it provides precise temperature control that maintains the integrity and freshness of perishable items throughout the cold chain.

What sets the Gen 2 Tote apart is its ability to operate silently, without vibration or harmful emissions. This makes it suitable for deployment in a wide range of environments, including hospitals, laboratories, and food service facilities, where noise and air quality are critical factors.

The Gen 2 Tote’s intelligent design integrates advanced sensors and monitoring systems, allowing real-time tracking of temperature, humidity, and other crucial parameters. This enables proactive management and immediate intervention in case of any deviations, ensuring optimal product quality and safety.

Furthermore, the Gen 2 Tote’s modular and stackable design maximizes storage capacity and enhances operational flexibility. Its compact footprint allows for efficient use of space, while its lightweight construction enables easy handling and transportation.

By revolutionizing the solid-state cold storage industry, the Gen 2 Tote is empowering businesses to streamline their operations, reduce waste, and enhance customer satisfaction. Its game-changing technology sets a new standard for temperature control, paving the way for a more sustainable and efficient future in cold chain fulfillment.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More